A comparative study on efficacy and safety profile of risperidone and iloperidone in patients of schizophrenia: randomized controlled study

Swathi Acharya, V. Srinivasa, S. Kotresh, Sharanappa Mulimani, Anithraj Bhat, Manohar Bhat


Background: Antipsychotics are most commonly used as first line therapy for schizophrenia. Treatment with antipsychotics is marked by poor compliance, drug discontinuation and frequent switching attributable to lack of efficacy of recently introduced atypical antipsychotics. The objectives of this study was to compare the efficacy and safety profile of risperidone, most commonly used drug with iloperidone,a recently introduced antipsychotic.

Methods: In this prospective, randomized open label 6-week study, 80 patients with diagnosis of Schizophrenia were randomized to two groups to receive either risperidone (4-8 mg) or iloperidone (6-24 mg). Their efficacy was assessed using reduction in PANSS score and safety profile was assessed by monitoring the adverse effects during follow-up visits at 2, 4, 6 weeks.

Results: Efficacy parameter, PANSS score showed significant reduction in both groups as compared to baseline values after 6 weeks. But there were no significant differences between two groups. The safety profile assessed by comparison of adverse effects showed statistically significant differences between the groups (<0.01).

Conclusions: Iloperidone with better extrapyramidal side effect profile and equivalent efficacy can be considered as good alternative to risperidone in schizophrenia treatment.


Risperidone, Iloperidone, Schizophrenia

Full Text:



WHO. Factsheet: Schizophrenia, 2015. Available at Accessed 20 November 2015.

Schizophrenia Facts and statistics. Available at http://www. Accessed 20 November 2015.

Shiv G, Parth SM. Drug emergent metabolic syndrome in patient with schizophrenia receiving atypical antipsychotics. Indian Journal of Psychiatry. 2011;53(2):109-16.

Cannon TD, Cadenhead K. Prediction of psychosis in high-risk youth: a multi-site longitudinal study in North America. Archives of General Psychiatry. 2008;65(1):28-37.

Wulf RB, Hans JS, Jim van OS, Anita RR. Size of burden of schizophrenia and psychotic disorders. Europea Neuro Psycho Pharmacology. 2005;15:399-409.

Lambert TJ, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. Med J Aust. 2003;178:67-70.

Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10:79-104.

Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-96.

Donal EN, Addington. Efficacy and tolerability of ziprosidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8 weeks double blind multicenter trial. J clinical psychiatry. 2004;65:12

Lieberman JA, Stroup TS, McEvoy JP. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-23.

Silvio C, Luca P, Alless AN. New atypical antiphyschotics for schizophrenia: iloperidone. Drug Des Devel ther. 2010;4:33-48.

Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuro Psycho Pharmacology. 2001;25:904-14.

John MG, Sukanta S, Joy W, Ossama ES, Clare MC, David C. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Medicine. 2004;2:13.

Andr A, Ren SK, Jean-PS. Sex differences in the risk of schizophrenia; evidence from meta-analysis. Arch Gen Psychiatry. 2003;60(6):565-71.

Parmanand K, Ruchita S, Aarya KR. An overview of Indian research in schizophrenia. Indian J Psychiatry. 2010;52(1):159-72.

Sukanta S, David C, Joy W, John MG. A systematic review of the prevalence of schizophrenia. PLos medicine. 2005;2(5):141:413-32.

Häfner H, Löffler W, Maurer K, Hambrecht M, An der Heiden W. Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia; Acta Psychiatrica Scandinavica. 1999;100:105-18.

Steven GP, Robert EL, Rosarelis T, Curt DW. Efficacy of iloperidone in the treatment of schizophrenia initial phase 3 studies. Journal of Clinical Psychopharmacology. 2008;28(2);4-11.

Peter JW, Andrew JC, Mihael HP, Curt DW. Safety profile of iloperidone a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol. 2008;28:12-9.

John MK, John L, Eugene L, Michael DM, Curt DW. Long-term efficacy and safety of iloperidone results from phase 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol. 2008;28:29-35.